Latest Prodrugs Stories
NEW YORK, April 20, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Chelsea's Northera (droxidopa) product, an...
Parker Waichman LLP is Already Representing Dozens of Plaintiffs in Plavix Gastrointestinal and Cerebral Bleeding Side Effect Lawsuits New York, NY (PRWEB) April 13, 2012 Parker Waichman LLP, a national law firm representing people injured by defective drugs, is investigating lawsuit claims on behalf of people who allegedly suffered severe bleeding side effects as a result of Plavix, a blood thinner made by Bristol -Myers Squibb Company and Sanofi-Aventis U.S., L.L.C. Parker Waichman LLP...
Developed in Canada and conducted by researchers from the University of Ottawa Heart Institute, in partnership with Spartan Bioscience, the world's first bedside genetic test has received acknowledgment by The Lancet, the world's leading general medical journal. The article Point-of-care genetic testing for personalization of antiplatelet treatment (RAPID GENE): a prospective, randomized, proof-of-concept trial, reports on the use of a simple cheek swab test, the Spartan RX CYP2C19,...
A two-drug combination is one of the most promising advances in decades for the treatment of tuberculosis (TB) — a disease that kills 2 million people annually — a scientist reported today at the 243 National Meeting & Exposition of the American Chemical Society (ACS). The treatment, which combines two medications already approved by the U.S. Food and Drug Administration (FDA), delivers a knockout punch to forms of TB that shrug off other antibiotics. ACS, the world's largest...
LOS ANGELES, March 15, 2012 /PRNewswire/ -- LA Weekly Reporter Gene Maddaus sure knows how to write a sensational story with a headline intended to grab the attention of his readers. He did just that with his recent LA Weekly story on Joshua Macciello, the unknown man who made a bid to buy the Los Angeles Dodgers. The only problem with Maddaus' ambitious investigative report is that it includes incorrect information. While interviewing anyone who would take his calls, Maddaus did...
SAN DIEGO, Feb. 29, 2012 /PRNewswire/ -- Essentialis, Inc., today announced Phase 2b trial results for its investigational compound DCCR demonstrating a reduction in triglyceride (TG) levels by 30 to 40 percent in patients whose TG levels exceeded 500 mg/dL (Very High Triglycerides [VHTG]). The study included an arm combining DCCR with fenofibrate treatment (Abbott Laboratories' Trilipix® (fenofibric acid)); in the combination arm, DCCR was shown to be additive to fenofibrate for...
Opioid-dependent individuals who want to kick the habit typically begin the road to recovery with detoxification. But detox is ineffective as a stand-alone treatment, with relapse rates ranging from 65% to 80% just one month after discharge. New research published online today in the journal Addiction reveals that individuals with substance use disorders may be as much as ten times more likely to stay abstinent when they have access to drug-free recovery housing and day-treatment programs...
A new report from researchers at the Drexel University School of Public Health identifies patterns in the misuse of illicit drugs among young adults who also misuse prescription drugs. The report, “Misuse of Prescription and Illicit Drugs among High-Risk Adults” in Los Angeles and New York, was recently published in the first issue of the Journal of Public Health Research. This is the first report to compare patterns of prescription and illicit drug misuse among high-risk young...
Tokyo, Jan 16, 2012 - (JCN Newswire) - Nobelpharma Co. Ltd and Eisai Co. Ltd announced today that they will launch the anticonvulsant agent Fostoin 750 mg for Injection (fosphenytoin sodium hydrate, "fostoin") on January 17. Developed in Japan by Nobelpharma, Fostoin will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.Fostoin is a water-soluble prodrug of phenytoin injection, a drug that has long been used...
CINCINNATI, Jan. 12, 2012 /PRNewswire/ -- Prasco® Laboratories announced today it has entered into an agreement with Shire (NASDAQ: SHPGY) for the distribution in the U.S. of the Authorized Generic version of Carbatrol® (Carbamazepine) Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths. Carbamazepine Extended-Release Capsules are AB-rated, therapeutically equivalent and substitutable for the brand Carbatrol®. The product will be distributed in the U.S. under the...
